Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11338

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Live official records

Open in full search

Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions: Pazopanib, Placebo oral capsule; Drug
Lead sponsor: Cure HHT; Other
Eligibility: 18 Years to 85 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more

Conditions: Proteinuric Kidney Disease
Interventions: VX-147, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 223
States / cities: Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more

Conditions: Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions: Cilostazol 100 mg Tablets, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 52
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 19 more

Conditions: Kidney Stone
Interventions: vacuum assisted sheath, passive suction via conventional sheath; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Parkinson Disease
Interventions: High intensity stationary cycling; Other
Lead sponsor: Jay Alberts; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Parkinson Disease, Freezing of Gait
Interventions: Multiple Deep Brain Stimulation (DBS) Conditions, Moving Overground in a Virtual Environment (MOVE), Cleveland Clinic Stair Ambulation and Functional Evaluation of Gait (SAFE-Gait); Other · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 29 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Breast Cancer
Interventions: Study Device Arm; Combination Product
Lead sponsor: Lumicell, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Mobile, Alabama • Scottsdale, Arizona • Palo Alto, California + 11 more

Conditions: Optic Nerve
Interventions: Ocular Ultrasound; Procedure
Lead sponsor: Cleveland Clinic Akron General; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Akron, Ohio

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Live official records

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Cilostazol for Prevention of Recurrent Stroke Trial

Diagnosing Epilepsy To EffeCT Change

Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis

Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial

Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Care in Multiple Sclerosis (MS)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Investigation of Novel Surgical Imaging for Tumor Excision

Measurement of the Optic Nerve Sheath Diameter